




1. GTN solution must be administered from a 30 ml syringe using an infusion pump.
2. Record baseline observations of blood pressure (BP) and heart rate (HR).
3. The initial infusion rate should be set at 1 mL/hour unless otherwise instructed by medical staff.
4. Adjust the infusion rate according to the guidance in the flowchart below to a maximum of 10ml/hour
5. Re-check observations and symptoms 15 minutes after starting the infusion and after each infusion rate change.
6. If infusion rate is not changed, re-check observation and symptoms every 30minutes for the first hour and then every hour.
7. If the infusion is reduced or stopped due to a low BP inform medical staff (senior doctor).
8. Check the residual (volume remaining in the syringe) at least every hour.
9. **Inform medical staff if systolic BP falls below 90mmHg.**
10. When the infusion is to be discontinued, reduce the rate by 1mL/hour every hour until stopped.

**CONTRAINDICATIONS:**

- Cardiogenic shock
  - Aortic or mitral valve stenosis,
  - Hypertrophic obstructive cardiomyopathy
  - Severe anemia,
  - Severe cerebral haemorrhage
  - Head trauma
  - Uncorrected hypovolaemia and hypotensive shock
  - Constrictive pericarditis
  - Pericardial tamponade
  - Toxic pulmonary oedema.
  - Conditions associated with an increased intracranial pressure
  - Hypersensitivity to the active substance, other nitrates or any of the excipients
- Cautious administration in patients using phosphodiesterase inhibitors type 5 (PDE5) (e. g. Sildenafil, Vardenafil, Tadalafil) may amplify the vasodilator effects of Glyceryl Trinitrate resulting in severe hypotension

**SIGNS OF SENSISTIVITY TO INFUSION**

- Fall in systolic blood pressure  $\leq 90$  mmHg
- Pallor
- Sweating
- Weak pulse•
- Collapse
- Dizziness
- Nausea



## **Documentation Control**

Development of Guideline:	Alina Paunescu, Emergency Medicine Consultant
Consultation with:	Cardiology (Dr Baron) Pharmacy (Esther Kirk, James Kerr)
Approved By:	ED - August 2023 Pharmacy - August 2023 Medical Division - Oct 2023
Review Date:	October 2026
Key Contact:	Alina Paunescu